Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study
Frontiers in Immunology2018Vol. 9, pp. 2195–2195
Citations Over TimeTop 10% of 2018 papers
Abstract
Patients with steroid refractory gastrointestinal (GI) tract graft- vs.-host disease (GvHD) face a poor prognosis and limited therapeutic options. To accurately assess the efficacy and safety of fecal microbiota transplantation (FMT) in treating steroid refractory GI tract GvHD, we conducted a pilot study involving eight patients. Having received FMTs, all patients' clinical symptoms relieved, bacteria enriched, and microbiota composition reconstructed. Compared to those who did not receive FMT, these eight patients achieved a higher progression-free survival. FMT can serve as a therapeutic option for GI tract aGVHD, but its effectiveness and safety need further evaluations. Clinical Trial Registration: NCT03148743.
Related Papers
- → Sequential rescue therapy in steroid-refractory ulcerative colitis(2014)7 cited
- → Mo1954 – Fecal Microbiota Transplantation is Safe and Effective for the Treatment of Clostridium Difficile Infection in Patients with Liver Cirrhosis(2019)2 cited
- → Su1414 Efficacy and Safety of Sequential Rescue Treatments in Steroid Refractory Ulcerative Colitis Experience(2014)
- → P452 Long-term efficacy and safety of cyclosporine as a rescue therapy in acute, steroid-refractory severe ulcerative colitis(2013)
- → Erratum to Empowering with Rescue Therapy: A Rescue for More Than Just Seizures(2022)